Q&A on practical aspects related to the implementation of the gradual roll-out of Eudamed pursuant to the MDR and IVDR, as amended by Regulation (EU) 2024/1860 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain in vitro diagnostic medical devices
News & Trends
Procurar
Recentes
- FARMACOVIGILÂNCIA avançada: ““Excelente! Organizada e abrangente !”
- Study on the deployment of AI in healthcare Final report
- Boas Práticas de Fabrico . GMP 2025: “Formação foi muito útil a nível de aplicabilidade “
- Conducting Clinical Trials With Decentralized Elements. Guidance for Industry, Investigators, and Other Interested Parties
- COMMISSION IMPLEMENTING REGULATION (EU) 2025/2086 of 17 October 2025
- Main root causes of shortages: Analysis of reported root causes during 2022 & 2023
- EUDAMED Release note v 2.18.0
- The ICH E2D(R1) Guideline reaches Step 4 of the ICH Process

